Supplemental Table 1

	Average - Baseline	Average - After PHC-102 SPECT/CT	Reference values	Units
Blood Count				
Erythrocytes	4.1	3.9	4.4 - 5.8	T/L
Hemoglobin	11.8	11.2	13.5 - 18.0	g/dL
Hematocrit	34.5	32.7	40.0 - 52.0	%
MCV	84.6	84.2	78.0 - 98.0	fL
MCH	28.9	28.8	27.0 - 33.0	pg
MCHC	34.2	34.2	30.0 - 36.0	g/dL
Erythrocytes (Fraction)	14.0	13.8	11.0 - 16.0	%
Platelets	202.8	226.4	150 - 350	G/L
Mean Platelets Volume	11.3	11.1	7.0 - 13.0	fL
Leukocytes	7.6	8.9	4.0 - 10.0	G/L
Differential Count				
Neutrophiles (absolut)	4.0	6.2	2.0 - 7.5	G/L
Neutrophiles (relative)	61.2	71.1	50.0 - 75.0	%
Lymphocytes (absolut)	1.7	1.4	1.0 - 4.0	G/L
Lymphocytes (relative)	26.8	16.9	25.0 - 40.0	%
Monocytes (absolut)	0.6	0.8	0.0 - 1.2	G/L
Monocytes (relative)	8.2	9.0	0.0- 12.0	%
Eosinophils (absolut)	0.2	0.2	0.0 - 0.4	G/L
Eosinophils (relative)	3.3	2.6	0.0 - 4.0	%
Basophils (absolut)	0.0	0.0	0.0 - 0.1	G/L
Basophils (relative)	0.5	0.5	0.0 - 1.0	%
aPTT	39.1	36.1	27.0 - 41.0	s
Fibrinogen - Clauss	488.0	391.0	200 - 400	mg/dL
Clinical Chemistry				
Sodium	140.3	137.7	136 - 145	mmol/L
Potassium	4.7	4.4	3.5 - 5.1	mmol/L
Chloride	99.6	99.0	98 - 107	mmol/L
Calcium	6.3	2.2	2.20 - 2.55	mmol/L
Inorganic Phosphate	1.2	1.2	0.81 - 1.45	mmol/L
Magnesium	1.0	1.1	0.66 - 1.07	mmol/L
Creatinine	0.9	1.0	0.70 - 1.20	mg/dL
Urea	15.4	14.9	8.0 - 23.0	mg/dL
Bilirubin (total)	2.1	2.1	0.0 - 1.2	mg/dL
Hemoglobin (free)	45.0	33.8	< 4	mg/dL
Albumin	41.8	37.0	35.0 - 52.0	g/L
ASAT (GOT)	41.2	17.3	< 50	U/L
ALAT (GPT)	38.8	27.8	< 50	U/L
Gamma - GT	59.2	35.8	< 60	U/L

Laboratory parameters before and after PHC-102 SPECT/CT microdosing procedure. Overall profile was not altered by administration of PHC-102 as evident by the comparison of blood count and clinical chemistry values calculated as average of data available from the five patients imaged.

Supplemental Table 2

Batch	Purity HPLC [%]	Purity TLC [%]	Starting activity [MBq]	Activity product [MBq]	Specific activity [MBq/µg]*
I	95.2	99.76	2070	1450	29
II	99.86	98.88	1400	1030	20.6
III	95.1	99.57	1150	954	19.08
IV	94.5	97.08	1570	1299	25.98
V	93.7	100	1950	1132	22.64
Average	95.672	99.058	1628	1173	23.46

Radiochemical incorporation and specific activity prior dilution of each different PHC-102 batch (each different batch corresponds to material prepared for each different patient imaged with PHC-102 SPECT/CT procedure). The product solution was diluted with a cold PHC-101 solution to obtain a final activity of 800 MBq/50µg.

Supplemental Table 3

Target Organ	ICRP-103 ED - Patient 1	ICRP-103 ED - Patient 2	ICRP-103 ED - Patient 3	ICRP-103 ED - Patient 4	ICRP-103 ED - Patient 5
Brain	2.50E-02	1.17E-08	1.76E-02	5.96E-03	1.21E-04
Gallbladder Wall	9.00E-02	4.85E-01	3.32E-02	3.33E-02	1.20E-02
Small Intestine	4.46E-01	1.02E-01	1.53E-01	1.01E-01	1.22E-02
Stomach Wall	5.93E+00	8.49E+02	7.16E+00	4.49E+00	4.23E+00
Kidneys	2.81E-01	1.22E+00	3.54E-01	2.63E-01	2.23E-01
Liver	5.49E-01	6.45E+00	6.03E+00	2.15E-01	7.03E-02
Lung	5.58E-01	2.69E+01	3.78E-01	2.97E-01	1.79E-01
Salivary Glands	2.72E-02	8.68E-02	5.66E-02	7.40E-03	3.75E-04
Spleen	8.74E-02	4.89E+00	6.09E-02	5.32E-01	4.14E-02

Total absorbed dose (mSv) to each organ after presented for each individual patient imaged with PHC-102 SPECT/CT procedure. Calculations are based on data at the three time points studies (30 min, 2 hours and 6 hours after intravenous administration of PHC-102).